Clinical Trial Update: A Study of NDV-01 (Sustained-release Gemcitabine-docetaxel) in Participants With Non-muscle Invasive Bladder Cancer [Phase 3]

View source ↗

Summary

Relmada Therapeutics is evaluating NDV-01, a sustained-release gemcitabine-docetaxel formulation, in Phase 3 for non-muscle invasive bladder cancer. The study i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer
• Non-muscle Invasive Bladder Cancer
• Urothelial Carcinoma of the Bladder

Drugs mentioned

• NDV-01 (Sustained-release Gemcitabine-docetaxel) (Gemcitabine-docetaxel sustained-release formulation)

Snippet

Sponsor: Relmada Therapeutics, Inc. | Conditions: Bladder (Urothelial, Transitional Cell) Cancer, Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive) | Phase 3 | Status: NOT_YET_RECRUITING